Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

At the 15mg dose, participants showed a sustained average weight loss of 22.9% during the three-year treatment. Credit: SB ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September, and according to ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Amgen is testing MariTide as a once-monthly shot, making it a promising potential rival to the weekly blockbuster weight-loss injections from Novo Nordisk and Eli Lilly. Tuesday's stock decline lopped ...